Minimal Important Difference (MID) of Response to the Hepatitis-C Virus Patient Reported Outcomes (HCV-PRO) Instrument in a Trial of Pegylated Interferon/Ribavirin (pegIFN/RBV) and Direct-Acting-Antivirals (DAA)

✍ Scribed by Baran, R.W.; Anderson, R.T.; Dietz, B.; Gooch, K.

• Book ID: 122240424
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 80 KB
• Volume: 16
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2013.08.233